152 related articles for article (PubMed ID: 38499069)
1. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Wang L; Lin L; Zhou W
Pharmacol Ther; 2024 May; 257():108634. PubMed ID: 38499069
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
[TBL] [Abstract][Full Text] [Related]
5. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma.
Teng Y; Ding X; Li W; Sun W; Chen J
Technol Cancer Res Treat; 2022; 21():15330338221075174. PubMed ID: 35313780
[No Abstract] [Full Text] [Related]
10. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.
Liu QQ; Wang XX; Ji H; Dou QY; Zhang HM
Med Oncol; 2024 Mar; 41(5):91. PubMed ID: 38526607
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
[TBL] [Abstract][Full Text] [Related]
12. Prognostic nomogram model for selecting between transarterial chemoembolization plus lenvatinib, with and without PD-1 inhibitor in unresectable hepatocellular carcinoma.
Sheng Y; Wang Q; Liu H; Wang Q; Chen W; Xing W
Br J Radiol; 2024 Feb; 97(1155):668-679. PubMed ID: 38303541
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of transarterial chemoembolization plus lenvatinib in the treatment of advanced hepatocellular carcinoma: A meta-analysis.
Li D; Liu S; Cheng C; Xu L; Zhao P
Medicine (Baltimore); 2023 Sep; 102(35):e34811. PubMed ID: 37657057
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis.
Zhou C; Chang B; Xiang Z; Li Z; Wu C; Bai M; Jiang Z; Huang M; Chen J
Acad Radiol; 2024 May; ():. PubMed ID: 38760273
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis.
Zhao S; Zhou M; Wang P; Yang J; Zhang D; Yin F; Song P
Technol Cancer Res Treat; 2022; 21():15330338221133640. PubMed ID: 36259214
[No Abstract] [Full Text] [Related]
18. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.
Wu HX; Ding XY; Xu YW; Yu MH; Li XM; Deng N; Chen JL
World J Gastroenterol; 2024 Feb; 30(8):843-854. PubMed ID: 38516240
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib.
Wang J; Zhao M; Han G; Han X; Shi J; Mi L; Li N; Yin X; Duan X; Hou J; Yin F
Technol Cancer Res Treat; 2023; 22():15330338231166765. PubMed ID: 37161343
[No Abstract] [Full Text] [Related]
[Next] [New Search]